Rifaximin 400 mg - Uses & Indications

What is Rifaximin?

• Katzung's Basic and Clinical Pharmacology, 16th Ed.

FDA-Approved Indications

1. Traveler's Diarrhea (most common use of 400 mg dose)

• Dose: Rifaximin 400 mg twice daily OR 200 mg three times daily for 3 days
• Effective against non-invasive E. coli strains (the most common cause of traveler's diarrhea)
• Important limitation: NOT effective against invasive pathogens such as Campylobacter, Salmonella, and Shigella spp. Azithromycin is preferred when invasive pathogens are suspected
• Single-dose rifaximin combined with loperamide has been shown comparable to azithromycin and levofloxacin for acute watery diarrhea
• Also used at 200 mg twice daily for chemoprophylaxis in travelers at high risk
• Goldman-Cecil Medicine; Rosen's Emergency Medicine; Goodman & Gilman's

2. Hepatic Encephalopathy (HE)

• Dose: Rifaximin 400 mg every 8 hours (three times daily)
• Used alongside lactulose (30-60 g/day) for managing and preventing recurrence of HE
• Reduces ammonia-producing gut bacteria without significant systemic effects
• A case-control study also described benefit in preventing spontaneous bacterial peritonitis (SBP) in patients with HE, though dedicated SBP prophylaxis data are limited
• Rosen's Emergency Medicine; Sleisenger & Fordtran's GI and Liver Disease

3. Irritable Bowel Syndrome with Diarrhea (IBS-D) - (higher dose)

• Standard FDA-approved dose: 550 mg TID for 14 days (not the 400 mg form)
• However, 400 mg TID for 10 days was studied and shown superior to placebo for global IBS symptoms and bloating in earlier trials
• The 400 mg dose improved global symptoms (36.4% vs 21.0% with placebo) and was effective throughout a 10-week follow-up
• Meta-analysis of 5 studies: rifaximin more efficacious than placebo (OR 1.57; NNT ~10)
• Up to 2 additional retreatment courses are allowed for recurrent IBS-D
• Yamada's Textbook of Gastroenterology, 7th Ed.

Off-Label / Emerging Uses

Key Pharmacology Points

• Mechanism: Inhibits beta subunit of bacterial DNA-dependent RNA polymerase
• Absorption: <0.5% systemic; very high fecal levels
• Drug interactions: Minimal - does NOT cause cytochrome P450 (CYP3A4)-mediated interactions unlike other rifamycins (rifampin)
• Common side effects: Nausea, abdominal pain, headache, upper respiratory infection, nasopharyngitis
• C. difficile risk: Very low; in retreatment IBS-D trials, only 1 case of C. diff was reported

Dosing Summary

Rifaximin in Pregnancy and Lactation

PREGNANCY

Regulatory Status

• Old FDA Pregnancy Category: C (teratogenic in animals; no adequate human data)
• Australia TGA Category: B1 (limited human data; no fetal harm seen in animals)
• Under current FDA labeling rules, the letter categories (A/B/C/D/X) are being phased out. The updated label reads: "May cause fetal harm - no data available on use in pregnant women; based on animal data, this drug may cause fetal harm."

Animal Teratogenicity Data

• In rats: teratogenic at 150-300 mg/kg/day, which is approximately 2x the therapeutic dose for traveler's diarrhea (based on plasma AUC), and <0.1x the hepatic encephalopathy dose
• Skeletal abnormalities (increased thoracolumbar vertebrae) were observed
• A pre/postnatal rat study showed no adverse effects on offspring development at doses up to 300 mg/kg/day when accounting for body surface area comparisons
• FDA Xifaxan Prescribing Information (2017)

Why Fetal Risk is Likely Low (But Not Zero)

• Systemic absorption is <0.5% after oral dosing - fetal exposure through transplacental transfer is expected to be very low
• Fecal concentrations are very high, but blood/systemic levels remain negligible
• Yamada's Textbook of Gastroenterology, 7th Ed.

Practical Clinical Guidance

"Consider avoiding use in first trimester, otherwise may use during pregnancy; no human data available, though risk of fetal harm not expected based on minimal systemic absorption; possible risk of teratogenicity in first trimester based on animal data at up to 33x recommended human doses."

• Yamada's Textbook of Gastroenterology, Table 40.8

LACTATION (Breastfeeding)

What the Data Shows

• No published human data on rifaximin levels in breast milk
• No published data on effects in breastfed infants
• No published data on effects on milk production
• NIH LactMed Database (last revised December 2024)

Theoretical Safety Reasoning

1. Maternal blood levels are negligible - so very little drug is available to pass into breast milk
2. Even if trace amounts entered milk, the infant's gut absorption of rifaximin would also be minimal
3. Systemic infant exposure and adverse effects are therefore considered very unlikely

Clinical Recommendation

• May use while breastfeeding based on pharmacokinetic reasoning - risk of infant harm and adverse effects on milk production not expected due to minimal maternal systemic absorption
• However, because no human data exist, an alternate drug may be preferred, especially when nursing a newborn or preterm infant
• Yamada's Textbook of Gastroenterology, Table 40.8; NIH LactMed

Summary Table

Bottom Line